|
The biotech is now looking to roll out Lisraya, the first targeted therapy for dermatomyositis, across the US via specialty pharmacies immediately.
|
 |
|
SK and Biohaven hope opakalim will show differential benefit to Xenon’s rival focal epilepsy drug, azetukalner, in an upcoming pivotal readout.
|
|
|
AusperBio’s total capital raised since 2024 has reached $360m.
|
|
|
The NDA is supported by two pivotal Phase III trials comparing K-911 0.1% with latanoprost 0.005%.
|
|
|
Study shows that those with low adherence of blood pressure-lowering drugs had significantly impaired therapeutic effect.
|
|
